JCA Pulse › Ongoing JCA
Ongoing JCARebisufligene etisparvovec: EU joint clinical assessment
Mucopolysaccharidosis type IIIA (Sanfilippo A) in children from birth to 18 years
- Regulatory review
- CHMP opinion
- EU authorised
- JCA report published
Overview
- Company
- Ultragenyx
- Therapy area
- Metabolic & genetic · Lysosomal storage
- Indication
- Mucopolysaccharidosis type IIIA (Sanfilippo A) in children from birth to 18 years
- Product type
- ATMP, Orphan designation
- EMA validation
- 01 Oct 2026
- JCA assessor
- AIHTA, Austria
- Co-assessor
- NCPHP, Hungary
- Regulatory status
- Under EMA review (validated Oct 2026).
- Pivotal evidence
- Transpher A (phase 1/2/3) + long-term follow-up (Single-arm vs natural history)
Scope
The PICO forecast
JCA Pulse forecasts 1–2 PICOs for Rebisufligene etisparvovec, with 2 candidate comparators. See the populations, comparators and likely outcomes the assessment is set to cover.
Evidence
Fit against the likely scope
Rebisufligene etisparvovec rests on Transpher A, evidence without a randomised comparator. Pro shows which likely PICOs it can answer, and where the gaps sit.
Comparisons
Trials and indirect comparisons
Pro maps every trial likely in the Rebisufligene etisparvovec dossier and projects the indirect comparison each comparator will need.
Countries
National translator and outlook
Austria and Hungary lead the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets.
Sources
Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.
From Evidaxia
- EU JCA dossiers and PICO scopingSupport from PICO scoping to the dossier
- JCA PICO scoping: process and preparationHow assessors set the scope
- EU JCA timelineEvery upcoming milestone